In essence T cells are the key to cancer immune surveillance.



Our complex immune system evolved to defend the body from pathogens such as bacteria and viruses but it can also be harnessed to fight cancerous and pre-cancerous cells. Its most potent weapons are T cells which can track down abnormal cells and eliminate them through the utilization of T cell receptors (TCRs) – clusters of proteins on every T cell that identify specific antigens displayed on the outside of cells.


At CBI, we are expanding the possibilities for cancer patients by fully engaging the T-cell receptor (TCR) complex which identifies tumor cells and directs the immune system to fight them.


About TCR²

At CBI, we have a bold vision – to help cure cancer by using our immune system in a more natural way. As a GLP research organization with a commitment to excellence and duty to science, CBI rises to today’s challenges by offering preclinical immunotherapy services, including bi-specific T cell engagers (BiTE) antibody testing, engineered T cells (CAR-T, TCR-T, etc.) efficacy, toxicology, and PK studies using xenograft and syngeneic tumor models.

CBI leads TRuC-T cell product candidate targeting solid tumors, gavocabtagene autoleucel (“gavo-cel”), is currently being studied in a a clinical trial to treat patients with:

    • mesothelin-positive non-small cell lung cancer (NSCLC)

    • ovarian cancer

    • malignant pleural/peritoneal mesothelioma

    • cholangiocarcinoma


TCR Services

  • Preliminary studies
  • Definitive study
    • Three antibody concentrations
    • 37 tissues
    • Three different human subjects
  • Extensive controls
  • Slide evaluation and interpretation
  • Internal peer review
  • In vitro cross-reactivity
  • In vivo binding of test articles
  • Analysis of potential treatment-related effects
  • Potential immune complex deposition in kidneys
  • Immunophenotyping
  • Monoclonal preclinical safety
    • Human
    • Humanized
    • Chimeric
    • Murine
  • Clinical trial support
    • Entry criteria
    • Biomarker
    • Proof-of-principle
  • Final Report
Comparative Biosciences, Inc’s. TCR2 services support the development of your candidate therapeutic antibodies by providing a powerful immunohistochemical assessment of potential cross-reactivity with a range of animal tissue. CBI has all the organizations defined in the relevant FDA and EMA submissions in accordance with the FDA’s recommendation and is in full compliance with local legal regulations and ethical norms.


Contact Comparative Biosciences, Inc. to discuss a scientific study program for T Cell Receptor Science Studies and Services.

Comparative Biosciences, Inc.    ·    Phone: 408.738.9260